News & Updates

Show Multimedia Only

Kids hard-hit by Delta; which ART performs best?

24 Oct 2021 by

That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.

Kids hard-hit by Delta; which ART performs best?

24 Oct 2021

Rapid antigen test: Don’t let perfect be the enemy of good

23 Oct 2021 by

While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.

Rapid antigen test: Don’t let perfect be the enemy of good

23 Oct 2021

Rapid COVID-19 testing: Is it as good in kids?

20 Oct 2021 by

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Rapid COVID-19 testing: Is it as good in kids?

20 Oct 2021

The role of apixaban in managing venous thromboembolism

01 Oct 2021

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), carries a significant morbidity risk. Risk factors for VTE include surgery, hospitalization, pregnancy, contraceptive use, older age, overweight, and obesity. Dr Lee Yuh Shan, a haematologist at Gleneagles Hospital and Mount Elizabeth Novena Hospital, Singapore, explains how newer drugs such as apixaban (Eliquis, Pfizer) address the challenges posed by conventional VTE management therapies.

The role of apixaban in managing venous thromboembolism

01 Oct 2021

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

30 Aug 2021 by

Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred choice of anticoagulants for stroke prevention in patients with atrial fibrillation (AF) in international guidelines. A leading expert in the field, Senior Consultant Cardiologist Dr Teo Wee Siong from Mount Elizabeth Medical Centre, Singapore, shared his insights on the 2021 EHRA* practical guide on NOACS in AF, how to personalize NOACs therapy, including apixaban (Eliquis, Pfizer), and manage difficult treatment scenarios. Dr Teo was past President of APHRS** and is currently President of HRAS***.

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

30 Aug 2021

Antigen rapid tests: The new COVID-19 strategy moving forward?

31 Jul 2021 by

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Antigen rapid tests: The new COVID-19 strategy moving forward?

31 Jul 2021

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

29 Jul 2021 by

A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

29 Jul 2021

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

29 Jul 2021 by

While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

29 Jul 2021

Advancing into the era of CAR T-cell therapies: Tisagenlecleucel in the treatment of B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma

21 May 2021 by

Tisagenlecleucel is the first therapy to be approved by the Singapore Health Sciences Authority under the Cell Tissue and Gene Therapy Product Regulations enacted on 1 March 2021. On 4 March 2021, Novartis organized a launch symposium for tisagenlecleucel, a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of paediatric and young adult patients with relapsed/refractory (r/r) acute lymphoblastic leukaemia (ALL) and adults with r/r diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The invited speakers were Prof Franco Locatelli from the Sapienza University of Rome, Italy, Dr Udo Holtick from the University Hospital of Cologne, Germany, and Dr Francesca Lim from Singapore General Hospital, Singapore. Prof William Hwang from National Cancer Centre, Singapore, chaired the symposium.

Advancing into the era of CAR T-cell therapies: Tisagenlecleucel in the treatment of B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma

21 May 2021

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

19 Mar 2021 by

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

19 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

Kids hard-hit by Delta; which ART performs best?

Kids hard-hit by Delta; which ART performs best?

Rapid antigen test: Don’t let perfect be the enemy of good

Rapid antigen test: Don’t let perfect be the enemy of good

Rapid COVID-19 testing: Is it as good in kids?

Rapid COVID-19 testing: Is it as good in kids?

The role of apixaban in managing venous thromboembolism

The role of apixaban in managing venous thromboembolism

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

2021 EHRA practical guide on NOACs in AF: What’s new, what’s hot

Antigen rapid tests: The new COVID-19 strategy moving forward?

Antigen rapid tests: The new COVID-19 strategy moving forward?

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

Antigen rapid test vs RT-PCR for COVID-19: What you need to know

Advancing into the era of CAR T-cell therapies: Tisagenlecleucel in the treatment of B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma

Advancing into the era of CAR T-cell therapies: Tisagenlecleucel in the treatment of B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib